HC Wainwright Issues Optimistic Estimate for SGMT Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate to ($0.45) from ($0.52), trimmed FY2026 loss forecasts and now models Sagimet reaching positive earnings by FY2029–FY2030, while reiterating a Buy rating and a $29 price target.
• Other brokers are bullish as well—Canaccord bumped its target to $49, nine analysts rate the stock Buy, and the consensus is a "Moderate Buy" with an average target of $28.63.
• The stock remains high‑risk: it trades around $7.90 (52‑week range $3.08–$11.41) with a market cap ≈$257M, a negative trailing P/E and a high beta (3.6), indicating volatility and ongoing losses.

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - HC Wainwright increased their Q1 2026 earnings estimates for shares of Sagimet Biosciences in a research report issued on Friday, May 1st. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.45) per share for the quarter, up from their prior forecast of ($0.52). HC Wainwright has a "Buy" rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Sagimet Biosciences' Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at $0.81 EPS and FY2030 earnings at $2.33 EPS.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last released its quarterly earnings data on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.14.

Several other equities analysts have also recently issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Sagimet Biosciences from $28.00 to $49.00 and gave the company a "buy" rating in a research report on Monday. Rodman & Renshaw started coverage on shares of Sagimet Biosciences in a research report on Thursday, March 26th. They issued a "buy" rating and a $28.00 price target for the company. Wall Street Zen upgraded shares of Sagimet Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. Guggenheim decreased their price target on shares of Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 29th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Sagimet Biosciences in a research report on Tuesday, April 21st. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $28.63.

Sagimet Biosciences Stock Performance

Shares of NASDAQ SGMT opened at $7.90 on Tuesday. Sagimet Biosciences has a 52-week low of $3.08 and a 52-week high of $11.41. The firm has a 50 day moving average price of $5.69 and a two-hundred day moving average price of $6.28. The stock has a market cap of $257.38 million, a P/E ratio of -5.03 and a beta of 3.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its stake in Sagimet Biosciences by 819.2% during the fourth quarter. Royal Bank of Canada now owns 4,927 shares of the company's stock worth $29,000 after acquiring an additional 4,391 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at $30,000. Wedmont Private Capital bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at $60,000. Virtu Financial LLC bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at $62,000. Finally, Hamilton Lane Advisors LLC bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at $66,000. 87.86% of the stock is owned by institutional investors.

Insider Buying and Selling at Sagimet Biosciences

In other news, CEO David Happel sold 12,101 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total transaction of $64,861.36. Following the completion of the sale, the chief executive officer directly owned 677,621 shares in the company, valued at $3,632,048.56. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 14.70% of the stock is currently owned by company insiders.

Trending Headlines about Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright materially raised near‑term EPS forecasts across Q1–Q4 2026 and lifted FY2026–FY2030 estimates, trimming expected losses in 2026 and projecting positive earnings by FY2029–FY2030; the firm reiterates a "Buy" rating and a $29 price target, signaling improved analyst confidence in Sagimet's pathway to profitability. HC Wainwright note (MarketBeat)
• Positive Sentiment: Canaccord Genuity raised its price target sharply from $28 to $49 and kept a "Buy" rating — a large upward revision that can attract momentum buyers and re-rate valuation expectations if the market accepts the new target. Canaccord target raise (Benzinga)
• Neutral Sentiment: HC Wainwright’s model still forecasts near‑term losses (FY2026 and FY2027 projected negative EPS) even as longer‑range years turn profitable; this implies investor gains depend on execution, trial/regulatory milestones or commercial progress that justify the out‑year upside. HC Wainwright note (MarketBeat)
• Negative Sentiment: Risk factors remain: the stock has a high beta (3.6) and a negative trailing PE, indicating volatility and continued losses — investors should weigh elevated price‑target optimism against execution risk and typical biotech binary outcomes.

About Sagimet Biosciences

Sagimet Biosciences NASDAQ: SGMT is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company's lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101's potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.